Polycythemia Pipeline constitutes 10+ key companies continuously working towards developing 10+ Polycythemia treatment therapies, analyzes DelveInsight.
Polycythemia Overview:
Polycythemia, also known as erythrocytosis, is characterized by an increase in red blood cell mass, which is typically identified through laboratory tests showing elevated hemoglobin and hematocrit levels. Polycythemia vera is a specific type of polycythemia, marked by the excessive production of all three cell lines. The clinical importance of erythrocytosis, regardless of the cause, is related to the heightened risk of thrombotic events due to increased blood viscosity. Moreover, in the case of polycythemia vera, there is a risk of progression to leukemia. This activity covers the evaluation, management, and potential complications of polycythemia vera, emphasizing the role of the interprofessional team in diagnosing and treating this condition.
Request for a detailed insights report on Polycythemia pipeline insights @ https://www.delveinsight.com/report-store/polycythemia-pipeline-insight?utm_source=abnewswire&utm_medium=market&utm_campaign=kpr
“Polycythemia Pipeline Insight 2025” report by DelveInsight provides a comprehensive analysis of the ongoing clinical development activities and growth prospects across the Polycythemia Therapeutics Market.
Key Takeaways from the Polycythemia Pipeline Report
DelveInsight’s Polycythemia pipeline report depicts a robust space with 10+ active players working to develop 10+ pipeline therapies for Polycythemia treatment.
A selective antisense oligonucleotide candidate for the treatment of PV that received orphan drug designation from the FDA in December 2024.
Approved by the FDA in November 2021, Besremi is the first interferon therapy specifically approved for PV. It has shown disease-modifying potential, including reducing JAK2 allele burden over the long term, which may help reduce the risk of disease progression over time.
Key Polycythemia companies such as Protagonist Therapeutics, Ionis Pharmaceuticals, Perseus Proteomics, Kartos Therapeutics, Imago BioSciences, Incyte Corporation, Italfarmaco, Lynk Pharmaceutical, Promedior, and others are evaluating new drugs for Polycythemia to improve the treatment landscape.
In September 2023, the FDA approved nedosiran, marketed as Rivfloza, for individuals aged nine and older with PH1 and relatively preserved kidney function. As an LDHA-directed small interfering RNA, nedosiran effectively lowers urinary oxalate levels.
Approved in November 2020 by both the U.S. Food and Drug Administration (FDA) and the European Union, lumasiran is an RNA interference therapeutic indicated for treating Polycythemia Type 1 (PH1) in adults and children. Clinical trials demonstrated a substantial reduction in urinary oxalate levels among treated patients.
Polycythemia Pipeline Analysis
The report provides insights into:
The report provides detailed insights into the key companies that are developing therapies in the Polycythemia Market.
The report also evaluates different therapeutic candidates segmented into early-stage, mid-stage, and late-stage of development for Polycythemia treatment.
It analyzes the key companies involved in targeted therapeutics development with respective active and inactive (dormant or discontinued) projects.
It navigates the emerging drugs under development based on the stage of development, route of administration, target receptor, monotherapy or combination therapy, a different mechanism of action, and molecular type.
Detailed analysis of collaborations (company-company collaborations and company-academia collaborations), licensing agreement, and financing details for future advancement of the Polycythemia market.
Download our free sample page report on Polycythemia pipeline insights @ https://www.delveinsight.com/sample-request/polycythemia-pipeline-insight?utm_source=abnewswire&utm_medium=market&utm_campaign=kpr
Polycythemia Emerging Drugs
Givinostat: Italfarmaco
Givinostat (ITF2357) is an orally available inhibitor of histone deacetylase (HDAC) with potential anti-inflammatory, anti-angiogenic, and anti-cancer properties. It targets class I and class II HDACs, causing the accumulation of acetylated histones, which triggers chromatin remodeling and alters gene expression patterns.
Bomedemstat: Imago BioSciences
Bomedemstat (IMG-7289) is a small molecule developed by Imago BioSciences that targets and inhibits lysine-specific demethylase 1 (LSD1 or KDM1A), an enzyme crucial for megakaryocyte production and the self-renewal of malignant hematopoietic stem or progenitor cells. In preclinical studies, bomedemstat showed strong in vivo efficacy both as a standalone treatment and in combination with other therapies, demonstrating effectiveness in various myeloid malignancy models, including myelofibrosis, essential thrombocythemia, and polycythemia vera.
Polycythemia Companies
There are around 10+ major companies working on developing therapies for polycythemia. Among them, Protagonist Therapeutics is one of the companies with drug candidates for polycythemia at the most advanced stage, specifically in Phase III.
DelveInsight’s report covers around 10+ products under different phases of clinical development like
Late stage products (Phase III)
Mid-stage products (Phase II)
Early-stage product (Phase I) along with the details of
Pre-clinical and Discovery stage candidates
Discontinued & Inactive candidates
Polycythemia pipeline report provides the therapeutic assessment of the pipeline drugs by the Route of Administration. Products have been categorized under various ROAs such as
Intravenous
Subcutaneous
Oral
Intramuscular
Polycythemia Products have been categorized under various Molecule types such as
Monoclonal antibody
Small molecule
Peptide
Download Sample Pages to Get an in-depth Assessment of the Emerging Polycythemia Therapies and Key Companies: Polycythemia Clinical Trials and advancements
Polycythemia Pipeline Therapeutic Assessment
• Polycythemia Assessment by Product Type
• Polycythemia By Stage
• Polycythemia Assessment by Route of Administration
• Polycythemia Assessment by Molecule Type
Download Polycythemia Sample report to know in detail about the Polycythemia treatment market @ Polycythemia Therapeutic Assessment
Table of Content
1. Report Introduction
2. Executive Summary
3. Polycythemia Current Treatment Patterns
4. Polycythemia – DelveInsight’s Analytical Perspective
5. Therapeutic Assessment
6. Polycythemia Late-Stage Products (Phase-III)
7. Polycythemia Mid-Stage Products (Phase-II)
8. Early Stage Products (Phase-I)
9. Pre-clinical Products and Discovery Stage Products
10. Inactive Products
11. Dormant Products
12. Polycythemia Discontinued Products
13. Polycythemia Product Profiles
14. Polycythemia Key Companies
15. Polycythemia Key Products
16. Dormant and Discontinued Products
17. Polycythemia Unmet Needs
18. Polycythemia Future Perspectives
19. Polycythemia Analyst Review
20. Appendix
21. Report Methodology
Media ContactCompany Name: DelveInsight Business Research LLPContact Person: Kritika RehaniEmail: Send EmailPhone: +14699457679Address:304 S. Jones Blvd #2432 City: Las VegasState: NevadaCountry: United StatesWebsite: https://www.delveinsight.com/
